Article thumbnail

Acute Visual Loss Induced by Dexamethasone During Neoadjuvant Docetaxol

By D.L. Gregory, C.D. Jones, E.R.E. Denton and A.N. Harnett

Abstract

We present a case of a female patient who developed acute onset of visual loss due to central serous retinopathy as a consequence of steroid premedication for docetaxol given as second line neoadjuvant chemotherapy for breast cancer. Central serous retinopathy is a recognised association with steroids but has not been previously reported in association with the management of solid tumours. Reduction in steroid dose and duration permitted recovery of her visual acuity while allowing completion of the prescribed chemotherapy regimen. An overview of the presentation, pathogenesis, aetiologies and management of central serous retinopathy is given

Topics: Case Report
Publisher: Libertas Academica
OAI identifier: oai:pubmedcentral.nih.gov:3161640
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1996). A Multicentre phase II study of the effi cacy and safety of Docetaxel as fi rst line treatment for advanced breast cancer: report of the clinical screening group of the EORTC’.
  2. (2007). Alterations of retinal pigment epithelium in central serous chorioretinopathy’.
  3. (1995). Bilateral central serous chorioretinopathy in a patient treated with systemic corticosteroids for non-Hodgkins Lymphoma’.
  4. (2006). Can long-term corticosteroids lead to blindness? A case series of central serous chroioretinopathy induced by corticosteroids’.
  5. (1994). Central serous chorioretinopathy and indocyanine green angiography’.
  6. (1993). Central serous chorioretinopathy and pregnancy’.
  7. (2003). Central serous chorioretinopathy associated with administration of sympathomimetic agents’.
  8. (1997). Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids’.
  9. (1997). Central serous chorioretinopathy complicating corticosteroid therapy’.
  10. (2004). Central serous chorioretinopathy in a patient taking Sildenafi l citrate’.
  11. (1993). Central serous chorioretinopathy in endogenous hypercortisolism’.
  12. (1996). Central serous chorioretinopathy in younger and older adults’.
  13. (2006). Central serous retinopathy and Helicobacter pylori’.
  14. (1996). Choroidal capillary and venous congestion in central serous chorioretinopathy’.
  15. (2004). Chronic central serous chorioretinopathy:photodynamic therapy’.
  16. (1995). Docetaxol is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening co operative group of the Europeon organisation for research and treatment of cancer’.
  17. (2003). Features of abnormal choroidal circulation in central serous chorioretinopathy’.
  18. (1995). Indocyanine green angiographic fi ndings in central serous chorioretinopathy’.
  19. (1984). Long term follow-up of central serous chorioretinopathy’.
  20. (2007). Ocular photodynamic therapy—standard applications and new indications (part 1). Review of the literature and personal experience’.
  21. (2003). Photodynamic therapy for chronic central serous chorioretinopathy’.
  22. (1994). Second EORTC clinical screening group(CSG) Phase II Trial of Taxotere as first line chemotherapy for advanced breast cancer’.
  23. (2004). Seventeen cases of central serous chorioretinopathy associated with systemic corticosteroid therapy’.
  24. (1993). Sub retinal exudative deposits in central serous chorioretinopathy’.
  25. (1996). Taxotere marketing authorisation Data on fi le.
  26. (1987). Type A behaviour and central serous chorioretinopathy’.